Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Ionis Pharmaceuticals Rose 12.9% in September

By Maxx Chatsko - Oct 11, 2018 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.

What happened

Shares of Ionis Pharmaceuticals (IONS 2.67%) jumped nearly 13% last month, according to data provided by S&P Global Market Intelligence. The move can be characterized as a recovery from the sudden and surprising news that Ionis and Akcea Therapeutics (AKCA) announced at the end of August, in which the U.S. Food and Drug Administration issued a complete response letter rejecting the application for the jointly developed rare-disease drug Waylivra.

The recovery didn't last long. In the first 10 days of October, shares of Ionis Pharmaceuticals gave up all of their gains from September and then a little bit more, settling near $44 per share. And that's despite receiving Food and Drug Administration marketing approval for a new rare disease drug. Should investors be concerned?

Hands holding up stacks of coins and a green arrow showing growth.

Image source: Getty Images.

So what

While the development duo didn't provide details explaining what issues the FDA had with Waylivra, investors can guess it has to do with safety. That's because some patients taking the drug during clinical trials saw an unsafe drop in blood platelet levels -- which may not be easy or possible to remedy, although Ionis Pharmaceuticals is better positioned to withstand the blow than Akcea Therapeutics.

That had investors worried about the upcoming FDA decision for Tegsedi, a treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR), which also came with a drop in blood platelet levels in some patients. However, the FDA approved the drug in early October, alleviating concerns.

Now what

Unfortunately for shareholders, removing the source of uncertainty for Tegsedi didn't help Ionis Pharmaceuticals stock escape the receding tide of the broader stock market. While the recent slide isn't influenced by factors within the company's control, the current $6 billion market cap may still represent a hefty premium for the business at the moment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$37.63 (2.67%) $0.98
Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.